The company's Biomea that is the lead program, icovamenib, is the first in the category of menin inhibitors directed to the treatment of both type 1 and type 2 diabetes that holds the potential to ...
Driving PID Temperature Control Innovation for Smarter Manufacturing CALIFORNIA, CA, UNITED STATES, March 31, 2026 ...
Analyst/Investor Day March 26, 2026 8:00 AM EDTCompany ParticipantsChristine Viau - Head of Investor RelationsDarryl White - ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results